No Data
No Data
Sansheng Pharmaceutical (01530.HK) spent HK$6.012 million to buy back 1 million shares on March 28
On March 28, Gelonghui Pharmaceutical (01530.HK) announced that it spent HK$6.012 million to buy back 1 million shares on March 28.
Sansheng Pharmaceutical (01530.HK) spent HK$5.744 million to buy back 1 million shares on March 27
On March 27, Gelonghui | Sansheng Pharmaceutical (01530.HK) issued an announcement. On March 27, 2024, it spent HK$5.744 million to repurchase 1 million shares at a repurchase price of HK$5.72-5.75 per share.
Sansheng Pharmaceutical (1530.HK): High performance growth, Davis double hit potential stocks
Recently, a secret document from the General Office of the National Development and Reform Commission called the “Draft for Solicitation of Comments on the Implementation Plan to Support the Development of Innovative Drugs in the Whole Chain” made waves in the market. The document elevates the development of innovative drugs to the level of a national strategy. It sees it as the key to promoting new quality productivity and seizing the high ground of the pharmaceutical industry, and is closely linked to the country's innovation-driven development, manufacturing power, and healthy China. It not only highlights the importance the government attaches to pharmaceutical innovation, but also marks the establishment of the bottom of pharmaceutical industry policy. At the same time, changes in the external macroeconomic environment have also brought new opportunities to the pharmaceutical sector. With the possibility of a cycle of interest rate cuts, long-term
[Hong Kong Stock Connect] Sansheng Pharmaceutical (01530) rebounded the market and rose 8.84%, and many institutions indicated that its performance was in line with expectations
Jinwu Financial News | Sansheng Pharmaceutical (01530) rebounded higher. As of press release, it reported HK$5.91, up 8.84%, with a turnover of HK$140 million. According to the news, Lyon published a report saying that Sansheng Pharmaceuticals's revenue last year was in line with expectations, but profits were 24.5% lower than the bank's expectations, mainly because sales and promotion expenses were higher than expected. Since pipeline products in preparation will only be launched after 2025, it is estimated that this year will be a relatively quiet year for the company. In response to the company's positive action to increase shareholder returns, the target price was raised from HK$5.7 to HK$6.2, reflecting a projected price-earnings ratio of 6.5 times, maintaining a “run”
Changes in Hong Kong stocks | Sansheng Pharmaceutical (01530) rose more than 7%, core product performance is steady, and the company suggests share buybacks
Sansheng Pharmaceutical (01530) rose more than 7%. As of press release, it rose 7% to HK$5.81, with a turnover of HK$566.979 million.
Sansheng Pharmaceutical (01530.HK) intends to exercise its power to repurchase shares
On March 21, Ge Longhui Pharmaceutical (01530.HK) issued an announcement. The board of directors of the company intends to exercise its power to repurchase shares on the open market at an appropriate time in accordance with the 2023 repurchase authorization and/or the general authorization granted by shareholders to repurchase shares at the company's annual general meeting of shareholders to be held on June 25, 2024. According to the 2023 repurchase mandate, the company was approved to repurchase up to 244 million shares on the Stock Exchange of Hong Kong Limited, accounting for 10% of the total number of shares issued on the date of the company's annual shareholders' meeting held on June 20, 2023. The directors plan to hold their annual general meeting in 2024
No Data